2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-150554
    Antitubercular agent-29 98%
    Antitubercular agent-29 (compound 6xa) is a potent agent resistant (DR) Mycobacterium tuberculosis (Mtb) inhibitor with MIC of 0.03 μg/mL against agent-susceptible (DS)-Mtb strains, MIC of 0.03-0.06 μg/mL against DR-Mtb strains, and favourable selectivity (SI>40) against Vero cells.
    Antitubercular agent-29
  • HY-150559
    SMS2-IN-3 2414240-89-2 98%
    SMS2-IN-3 is a potent and selective SMS2inhibitor (IC50=2.2 nM), significantly reduces the hepatic SM (22:0) levels.
    SMS2-IN-3
  • HY-150574
    CYP3A4-IN-1 2771297-34-6 98%
    CYP3A4-IN-1 (compound 5a) is a potent cytochrome P450 3A4 (CYP3A4) inhibitor with an IC50 value of 0.085 µM.
    CYP3A4-IN-1
  • HY-150581
    CYP3A4-IN-3 2562384-19-2 98%
    CYP3A4-IN-3 is a high-affinity specific inhibitor of cytochrome P450 3A4 (CYP3A4) with the IC50 value of 0.075 μM. CYP3A4-IN-3 is a ritonavir analogue, but with a simpler structure and twice the inhibitory effect of ritonavir. CYP3A4-IN-3 is used as an antiviral agent and immunosuppressant.
    CYP3A4-IN-3
  • HY-150584
    Chitin synthase inhibitor 3 2416338-26-4 98%
    Chitin synthase inhibitor 3 (compound 2d) is a potent chitin synthase inhibitor with an IC50 value of 0.16 mM, and MIC of 1 µg/mL against candida albicans. Antifungal activity.
    Chitin synthase inhibitor 3
  • HY-150588
    InhA-IN-3 900701-83-9 99.66%
    InhA-IN-3 (Compound TU12) is a Mycobacterium tuberculosis InhA (an enoyl ACP-reductase) inhibitor with an IC50 of 17.7 μM.
    InhA-IN-3
  • HY-150589
    InhA-IN-4 894309-72-9 98%
    InhA-IN-4 (TU14) is a Mycobacterium tuberculosis InhA (an enoyl ACP-reductase) inhibitor with an IC50 of 15.6 μM.
    InhA-IN-4
  • HY-150599
    HIV-1 inhibitor-43 2493426-43-8 98%
    HIV-1 inhibitor-43 is a potent HIV-1 inhibitor with an EC50 of 21.3 nM, 6.2 nM, < 0.7 nM and < 0.7 nM for Y188L, K103N-Y181C, K103N and Y181C, respectively. HIV-1 inhibitor-43 can reduce HIV-1 RNA and protein p24 expression.
    HIV-1 inhibitor-43
  • HY-150600
    NS2B/NS3-IN-7 3035421-16-7 98.59%
    NS2B/NS3-IN-7 (compound 26) is a highly potent Zika virus NS2B-NS3 protease inhibitor with a Ki value of 2.33 nM. NS2B/NS3-IN-7 can reduce amounts of ZIKV-infected cells.
    NS2B/NS3-IN-7
  • HY-150623
    SARS-CoV-2 nsp13-IN-2 522660-61-3 98%
    SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 42 μM against nsp13 ssDNA+ ATPase.
    SARS-CoV-2 nsp13-IN-2
  • HY-150624
    SARS-CoV-2 nsp13-IN-3 1015582-31-6 98%
    SARS-CoV-2 nsp13-IN-3 (Compound C3) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 32 μM against nsp13 ssDNA+ ATPase.
    SARS-CoV-2 nsp13-IN-3
  • HY-150625
    SARS-CoV-2 nsp13-IN-4 923140-39-0 98%
    SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC50 value of 57 μM. SARS-CoV-2 nsp13-IN-4 is agentlike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect.
    SARS-CoV-2 nsp13-IN-4
  • HY-150626
    SARS-CoV-2 nsp13-IN-5 912799-11-2 98%
    SARS-CoV-2 nsp13-IN-5 (compound C6) is a potent SARS-CoV-2 nsp13 inhibitor with IC50 values of 50 and 55 μM for ssDNA+ ATPase and ssDNA- ATPase. SARS-CoV-2 nsp13-IN-5 can be used for researching anti-COVID-19.
    SARS-CoV-2 nsp13-IN-5
  • HY-150632
    SARS-CoV-2 nsp13-IN-6 951588-85-5 98%
    SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structural protein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA+ ATPase and ssDNA- ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19.
    SARS-CoV-2 nsp13-IN-6
  • HY-150680
    SARS-CoV-2 nsp14-IN-1 2816165-02-1 98%
    SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases.
    SARS-CoV-2 nsp14-IN-1
  • HY-150699
    TXA6101 1459695-66-9 98%
    TXA6101 is a bacterial protein FtsZ (filamentous temperature-sensitive protein Z) inhibitor that inhibits bacterial division. TXA6101 has antimicrobial activity against MRSA isolates expressing either the G193D or G196S mutant FtsZ with the MIC value of 1 μg/mL, retains significant activity against the TXA707-resistant FtsZ mutant. TXA6101 can be used as a potential method against Gram-negative bacterial infections.
    TXA6101
  • HY-150754
    FtsZ-IN-4 2882904-64-3 98%
    FtsZ-IN-4 is an orally active FtsZ (filamenting temperature-sensitive mutant Z) inhibitor, exhibits excellent antibacterial activity. FtsZ-IN-4 shows good pharmaceutical properties with low cytotoxicity (CC50 >20 μg/mL).
    FtsZ-IN-4
  • HY-150766
    KPC-2-IN-1 2232877-85-7 98%
    KPC-2-IN-1, boronic acid derivative, is a potent KPC-2 inhibitor with Ki of 0.032 μM. KPC-2-IN-1 enhances the activity of cefotaxime in KPC-2 expressing E. coli. KPC-2-IN-1 exhibits well tolerated in human HEK-293 cells, which can be used for the study of E. coli resistance to β-lactam antibiotics.
    KPC-2-IN-1
  • HY-150767
    KPC-2-IN-2 3034185-71-9 98%
    KPC-2-IN-2 (Compound 6c) is a potent Klebsiella pneumoniae carbapenemase (KPC-2) inhibitor (Ki=0.038 μM). KPC-2-IN-2 can enhance the activity of cefotaxime in KPC-2 expressing Escherichia coli.
    KPC-2-IN-2
  • HY-150783
    SARS-CoV-2-IN-24 98%
    SARS-CoV-2-IN-24 (compound 7) is a potent papain-like protease (PLpro) inhibitor. SARS-CoV-2-IN-24 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. SARS-CoV-2-IN-24 can be used for SARS-CoV-2 research.
    SARS-CoV-2-IN-24
Cat. No. Product Name / Synonyms Application Reactivity